{"id":"NCT00678795","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis","officialTitle":"A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Cannabis Based Medicine (CBM) Extract, in Patients Suffering Detrusor Overactivity Associated With Multiple Sclerosis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-08","primaryCompletion":"2005-10","completion":"2005-10","firstPosted":"2008-05-16","resultsPosted":"2012-09-21","lastUpdate":"2023-05-03"},"enrollment":135,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Detrusor Overactivity","Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Sativex®","otherNames":["GW-10000-02"]},{"type":"DRUG","name":"Placebo","otherNames":["GW-4001-01"]}],"arms":[{"label":"Sativex","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in reducing the daily number of episodes on incontinence.","primaryOutcome":{"measure":"Change From Baseline in the Mean Daily Number of Incontinence Episodes at the End of Treatment","timeFrame":"0 - 10 weeks","effectByArm":[{"arm":"Sativex","deltaMin":-1.08,"sd":1.42},{"arm":"Placebo","deltaMin":-0.99,"sd":1.09}],"pValues":[{"comp":"OG000 vs OG001","p":"0.569"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["20829244"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":67},"commonTop":["Dizziness","Urinary tract infection Not Otherwise Specified","Headache Not Otherwise Specified","Vomiting Not Otherwise Specified","Nausea"]}}